{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:52:25Z","timestamp":1789829545614,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1996,4,1]],"date-time":"1996-04-01T00:00:00Z","timestamp":828316800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Neural Transmission"],"published-print":{"date-parts":[[1996,4]]},"DOI":"10.1007\/bf01276418","type":"journal-article","created":{"date-parts":[[2005,3,24]],"date-time":"2005-03-24T06:19:27Z","timestamp":1111645167000},"page":"421-432","source":"Crossref","is-referenced-by-count":23,"title":["Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease"],"prefix":"10.1007","volume":"103","author":[{"given":"A.","family":"Moser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Siebecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Vieregge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Jaskowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"K\ufffdmpf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1600-0773.1984.tb01998.x","volume":"55","author":"MM Airaksinen","year":"1984","unstructured":"Airaksinen MM, Saano V, Steidel E, Juvonen H, Huhtikangas A, Gynther J (1984) Binding of ?-carbolines and tetrahydroisoquinolines by opiate receptors of the ?-type. Acta Pharmacol Toxicol 55: 380?385","journal-title":"Acta Pharmacol Toxicol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/pgmj.65.764.358","volume":"65","author":"AK Banerjee","year":"1989","unstructured":"Banerjee AK, Falkai PG, Savidge M (1989) Visual hallucinations in the elderly associated with the use of levodopa. Postgrad Med J 65: 358?361","journal-title":"Postgrad Med J"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1111\/j.1471-4159.1993.tb07459.x","volume":"61","author":"P Celada","year":"1993","unstructured":"Celada P, Artigas F (1993) Plasma 5-hydroxyindole acetic acid as an indicator of monoamine oxidase A inhibition in rat brain and peripheral tissues. J Neurochem 61: 2191?2198","journal-title":"J Neurochem"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/0022-510X(91)90193-B","volume":"106","author":"AVT Cheng","year":"1991","unstructured":"Cheng AVT, Ferrier IN, Morris CM, Jabeen S, Sahgal A, McKeith IG, Edwardson JA, Perry RH, Perry EK (1991) Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. J Neurol Sci 106: 50?55","journal-title":"J Neurol Sci"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.505002","volume":"206","author":"MA Collins","year":"1979","unstructured":"Collins MA, Nijm WP, Borge GF, Teas G, Goldfarb C (1979) Dopamine related tetrahydroisoquinolines: significant urinary excretion by alcoholics after alcohol consumption. Science 206: 1184?1186","journal-title":"Science"},{"key":"CR6","first-page":"144","volume":"5","author":"JL Cummings","year":"1992","unstructured":"Cummings JL (1992) Psychosis in neurologic disease: neurobiology and pathogenesis. Neuropsychiatr Neuropsychol Behav Neurol 5: 144?150","journal-title":"Neuropsychiatr Neuropsychol Behav Neurol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/jnnp.34.5.502","volume":"34","author":"AR Damasio","year":"1971","unstructured":"Damasio AR, Antunes JL, Macedo C (1971) Psychiatric aspects in parkinsonism treated with L-dopa. J Neurol Neurosurg Psychiatry 34: 502?507","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF01245140","volume":"74","author":"P Dostert","year":"1988","unstructured":"Dostert P, Strolin Benedetti M, Dordain G (1988) Dopamine-derived alkaloids in alcoholism and in Parkinson's and Huntington's diseases. J Neural Transm 74: 61?74","journal-title":"J Neural Transm"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF02263481","volume":"1","author":"P Dostert","year":"1989","unstructured":"Dostert P, Strolin Benedetti M, Dordain G, Vernay D (1989) Enantiomeric composition of urinary salsolinol in parkinsonian patients after Madopar. J Neural Transm [P-D Sect] 1: 269?78","journal-title":"J Neural Transm [P-D Sect]"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF01245043","volume":"81","author":"P Dostert","year":"1990","unstructured":"Dostert P, Strolin Benedetti M, Bellotti V, Allievi C, Dordain G (1990) Biosynthesis of salsolinol, a tetrahydroisoquinoline alkaloid, in healthy subjects. J Neural Transm [Gen Sect] 81: 215?223","journal-title":"J Neural Transm [Gen Sect]"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0378-4347(00)83667-1","volume":"380","author":"M Gerlach","year":"1986","unstructured":"Gerlach M, Klaunzer N, Pruntek H (1986) Determination of L-dopa and 3-O-methyl dopa in human plasma by extraction using C18 cartridges followed by high performance liquid Chromatographic analysis with electrochemical detection. J Chromatogr 380: 379?385","journal-title":"J Chromatogr"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0165-0327(87)90048-6","volume":"13","author":"A Gjerris","year":"1987","unstructured":"Gjerris A, Werdelin L, Rafaelsen O, Ailing C, Christensen NJ (1987) CSF dopamine increased in depression: CSF dopamine, noradrenaline and their metabolites in depressed patients and in controls. J Affect Disord 13: 279?286","journal-title":"J Affect Disord"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","volume":"35","author":"RA Glennon","year":"1984","unstructured":"Glennon RA, Titeler M, McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35: 2505?251","journal-title":"Life Sci"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1176\/ajp.139.11.1526","volume":"139","author":"CG Goetz","year":"1982","unstructured":"Goetz CG, Tanner CM, Klawans HL (1982) Pharmacology of hallucinations induced by long-term drup therapy. Am J Psychiatry 139: 494?497","journal-title":"Am J Psychiatry"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF02257622","volume":"4","author":"P Hartikainen","year":"1992","unstructured":"Hartikainen P, Reinikainen KJ, Soininen H, Sirvi\u00f6 J, Soikkeli R, Riekkinen (1992) Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls. J Neural Transm [PD-Sect] 4: 53?68","journal-title":"J Neural Transm [PD-Sect]"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1471-4159.1993.tb05831.x","volume":"60","author":"S Kaakkula","year":"1993","unstructured":"Kaakkula S, Wurtman RJ (1993) Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbodopa on extracellular dopamine in the rat striatum. J Neurochem 60: 137?144","journal-title":"J Neurochem"},{"key":"CR17","first-page":"117","volume":"27","author":"HL Klawans","year":"1988","unstructured":"Klawans HL (1988) Psychiatric side effects during the treatment of Parkinson's disease. J Neural Transm [Suppl] 27: 117?122","journal-title":"J Neural Transm [Suppl]"},{"key":"CR18","first-page":"1750","volume":"150","author":"EC Lauterbach","year":"1993","unstructured":"Lauterbach EC (1993) Dopaminergic hallucinosis with fluoxetine in Parkinson's disease. Am J Psychiatry 150: 1750","journal-title":"Am J Psychiatry"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1212\/WNL.42.11.2111","volume":"42","author":"PA LeWitt","year":"1992","unstructured":"LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M (1992) Markers of dopamine metabolism in Parkinson's disease. Neurology 42: 2111?2117","journal-title":"Neurology"},{"key":"CR20","first-page":"49","volume":"12","author":"PC Mahalanobis","year":"1936","unstructured":"Mahalanobis PC (1936) On the generalized distance in statistics. Proc Natl Inst Sci India 12: 49?55","journal-title":"Proc Natl Inst Sci India"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF01245003","volume":"94","author":"W Maruyama","year":"1993","unstructured":"Maruyama W, Nakahara D, Dostert P, Takahashi A, Naoi M (1993) Naturally-occuring isoquinolines perturb monoamine metabolism in the brain: studied by in vivo microdialysis. J Neural Transm [Gen Sect] 94: 91?102","journal-title":"J Neural Transm [Gen Sect]"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/BF02335940","volume":"11","author":"G Meco","year":"1990","unstructured":"Meco G, Bonifati V, Cusimano G, Fabrizio E, Vanacore N (1990) Hallucinations in Parkinson's disease: neuropsychological study. Ital J Neurol Sci 11: 373?379","journal-title":"Ital J Neurol Sci"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S0140-6736(94)92511-9","volume":"343","author":"G Meco","year":"1994","unstructured":"Meco G, Alessandria A, Bonivati V, Giustini P (1994) Risperidone for hallucinations in levdopa-treated Parkinson's disease patients. Lancet 343: 1370?1371","journal-title":"Lancet"},{"key":"CR24","first-page":"149","volume":"40","author":"E Melamed","year":"1984","unstructured":"Melamed E, Hefti F (1984) Mechanism of action of short- and long-term L-dopa treatment. Adv Neurol 40: 149?170","journal-title":"Adv Neurol"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1111\/j.1471-4159.1992.tb10951.x","volume":"58","author":"M Minami","year":"1992","unstructured":"Minami M, Takahashi T, Maruyama W, Takahashi A, Dostert P, Nagatsu T, Naoi M (1992) Inhibition of tyrosine hydroxylase by R and S enantiomers of salsolinol, 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydro-isoquinoline. J Neurochem 58: 2097?2101","journal-title":"J Neurochem"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF01244872","volume":"92","author":"M Minami","year":"1993","unstructured":"Minami M, Maruyama W, Dostert P, Nagatsu T, Naoi M (1993) Inhibition of type A and B monoamine oxidase by 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines and their N-methylated derivatives. J Neural Transm [Gen Sect] 92: 125?135","journal-title":"J Neural Transm [Gen Sect]"},{"key":"CR27","first-page":"427","volume-title":"CNS barriers and modern CSF diagnostics","author":"A Moser","year":"1993","unstructured":"Moser A, Vieregge P, K\u00f6mpf D (1993) Cerebrospinal fluid dopamine metabolites levels after treatment with deprenyl in Parkinson's disease. In: Felgenhauer K, Holzgraefe M, Prange HW (eds) CNS barriers and modern CSF diagnostics. VCH publishers, New York, pp 427?429"},{"key":"CR28","first-page":"132","volume":"376","author":"A Moser","year":"1995","unstructured":"Moser A, Scholz J, Siebecker F (1995a) HPLC assay for quantitating salsolinol in the urine of patients with Parkinson's disease. Biol Chem Hoppe-Seyler 376: 132","journal-title":"Biol Chem Hoppe-Seyler"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0022-510X(95)00110-N","volume":"131","author":"A Moser","year":"1995","unstructured":"Moser A, Scholz J, Nobbe F, Vieregge P, B\u00f6hme V, Bamberg H (1995b) Presence of N-methyl-norsalsolinol in the CSF: correlations with dopamine metabolites of patients with Parkinson's disease. J Neurol Sci 131: 183?189","journal-title":"J Neurol Sci"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0197-0186(94)90024-8","volume":"25","author":"M Naoi","year":"1994","unstructured":"Naoi M, Maruyama W, Sasuga S, Deng Y, Dostert P, Ohta S, Takahashi T (1994) Inhibition of type A monoamine oxidase by 2(N)-methyl-6,7-dihydroxyisoquinolinium ions. Neurochem Int 25: 475?481","journal-title":"Neurochem Int"},{"key":"CR31","first-page":"212","volume":"60","author":"M Naoi","year":"1993","unstructured":"Naoi M, Dostert P, Yoshida M, Nagatsu T (1993) N-methylated tetrahydroisoquinolines as dopaminergic neurotoxins. Adv Neurol 60: 212?217","journal-title":"Adv Neurol"},{"key":"CR32","first-page":"271","volume":"40","author":"PA Nausieda","year":"1984","unstructured":"Nausieda PA, Glantz R, Weber B, Baum R, Klawans HL (1984) Psychiatric complications of levodopa therapy of Parkinson's disease. Adv Neurol 40: 271?277","journal-title":"Adv Neurol"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/0006-8993(81)90876-3","volume":"224","author":"T Origitano","year":"1981","unstructured":"Origitano T, Hannigan J, Collins MA (1981) Rat brain salsolinol and blood-brain barrier. Brain Res 224: 446?451","journal-title":"Brain Res"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF02260919","volume":"6","author":"EK Perry","year":"1993","unstructured":"Perry EK, Marshall E, Thompson P, McKeith IG, Collerton G, Fairbairn AF, Ferrier IN, Irving D, Perry RH (1993) Monoaminergic activities in Lewy body dementia: relation to hallucinosis and extrapyramidal features. J Neural Transm [PD-Sect] 6: 167?177","journal-title":"J Neural Transm [PD-Sect]"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/mds.870050310","volume":"5","author":"RF Pfeiffer","year":"1990","unstructured":"Pfeiffer RF, Kang J, Graber B, Hofman R, Wilson J (1990) Clozapine for psychosis in Parkinson's disease. Mov Disord 5: 239?242","journal-title":"Mov Disord"},{"key":"CR36","first-page":"918","volume":"247","author":"PA Pierce","year":"1988","unstructured":"Pierce PA, Peroutka SJ (1988) Antagonism of 5-hydroxytryptamine-2 receptor-mediated phosphatidyl-inositol turnover by D-lysergic acid diethylamide. J Pharmacol Exp Ther 247: 918?925","journal-title":"J Pharmacol Exp Ther"},{"key":"CR37","first-page":"259","volume":"40","author":"P Rondot","year":"1984","unstructured":"Rondot P, de Recondo J, Coignet A, Ziegler M (1984) Mental disorders in Parkinson's disease after treatment with L-dopa. Adv Neurol 40: 259?269","journal-title":"Adv Neurol"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/241439a0","volume":"241","author":"M Sandier","year":"1973","unstructured":"Sandier M, Bonham Carter SW, Hunter KR, Stern GM (1973) Tetrahydroisoquinoline alkaloides: in vivo metabolite of L-dopa in man. Nature 241: 439?443","journal-title":"Nature"},{"key":"CR39","first-page":"909","volume":"372","author":"W Stammel","year":"1991","unstructured":"Stammel W, Thomas H (1991) Interaction of tetrahydroisoquinoline alkaloids with opiat receptors in the rat brain. Biol Chem Hoppe-Seyler 372: 909?910","journal-title":"Biol Chem Hoppe-Seyler"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1080\/00032719308017488","volume":"26","author":"W Stammel","year":"1993","unstructured":"Stammel W, Thomas H (1993) A simple and rapid method for the seperation of the (R)- and (S)-enantiomers of the tetrahydroisoquinoline alkaloid salsolinol by high performanceliquid chromatography. Analyt Lett 26: 2513?2524","journal-title":"Analyt Lett"},{"key":"CR41","first-page":"169","volume":"77","author":"DG Standaert","year":"1993","unstructured":"Standaert DG, Stern MB (1993) Update on the management of Parkinson's disease. Contemp Clin Neurol 77: 169?183","journal-title":"Contemp Clin Neurol"},{"key":"CR42","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF01247112","volume":"78","author":"M Strolin Benedetti","year":"1989","unstructured":"Strolin Benedetti M, Dostert P, Carminati P (1989) Influence of food intake on the enantiometric composition of urinary salsolinol in man. J Neural Transm 78: 43?51","journal-title":"J Neural Transm"},{"key":"CR43","first-page":"207","volume":"60","author":"M Yoshida","year":"1993","unstructured":"Yoshida M, Ogawa M, Suzuki K, Nagatsu T (1993) Parkinsonism produced by tetrahydroisoquinoline or the analogues. Adv Neurol 60: 207?211","journal-title":"Adv Neurol"},{"key":"CR44","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/0140-6736(93)90327-D","volume":"341","author":"J Zoldan","year":"1993","unstructured":"Zoldan J, Friedberg G, Goldberg-Stern H, Melamed E (1993) Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 341: 562?563","journal-title":"Lancet"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01276418.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01276418\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01276418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T18:15:27Z","timestamp":1556648127000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01276418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1996,4]]}},"alternative-id":["BF01276418"],"URL":"https:\/\/doi.org\/10.1007\/bf01276418","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,4]]}}}